Letter by Bouatou et al Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation"

Bouatou, Yassine; El Biali, Myriam; Samer, Caroline Flora

doi:10.1161/CIRCULATIONAHA.116.022034

Scientific article

Letter

English

Letter by Bouatou et al Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation"

ContributorsBouatou, Yassine; El Biali, Myriam; Samer, Caroline Flora

Published inCirculation, vol. 134, no. 2, p. e3-4

Publication date2016

Abstract

Letter to the Editor.

Keywords

CYP3a
Drug drug interaction
Atrial Fibrillation

Affiliation

Faculté de médecine / Section de médecine clinique / Département d'anesthésiologie, pharmacologie, soins intensifs et urgences

Research group

Citation (ISO format)

BOUATOU, Yassine, EL BIALI, Myriam, SAMER, Caroline Flora. Letter by Bouatou et al Regarding Article, ‘Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation’. In: Circulation, 2016, vol. 134, n° 2, p. e3–4. doi: 10.1161/CIRCULATIONAHA.116.022034

Article (Published version)

Identifiers

PID : unige:85403
DOI : 10.1161/CIRCULATIONAHA.116.022034
PMID : 27400900

ISSN of the journal0009-7322

459views

3downloads

Creation07/20/2016 11:34:00 AM

First validation07/20/2016 11:34:00 AM

Update time03/15/2023 12:34:16 AM

Status update03/15/2023 12:34:16 AM

Last indexation01/16/2024 9:21:02 PM

Archive ouverte UNIGE

Letter by Bouatou et al Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation"

Letter to the Editor.

Technical informations